Clinical-stage firm GPN Vaccines raises US$10 million in a fully subscribed private placement to support manufacturing and regulatory filings for its Gamma-PN vaccine candidate.
GPN Vaccines has successfully secured US$10 million through a fully subscribed private placement, providing the necessary capital to advance its Gamma-PN vaccine candidate. The funding is specifically earmarked for critical Phase 2-enabling activities, including cGMP manufacturing, the expansion of OPA-testing capabilities, and the preparation of an Investigational New Drug (IND) application for the FDA.
The funds are designated for Phase 2-enabling activities, specifically cGMP manufacturing, OPA-testing expansion, and FDA IND submission.
The private placement is fully subscribed.
GPN Vaccines, Inc. has successfully closed a fully subscribed US$10 million private placement to accelerate its clinical development pipeline. The capital will fund Phase 2-enabling activities for the company's Gamma-PN vaccine, including cGMP manufacturing and the upcoming IND submission to the FDA.
The proceeds will support Phase 2-enabling activities for the Gamma-PN vaccine, specifically cGMP manufacturing, expansion of OPA-testing capabilities, and the preparation of an IND submission to the FDA.